A study on serum zonulin in chronic spontaneous urticaria patients … Original Research Article …

The Egyptian Journal of Immunology
E-ISSN (2090-2506)
Volume 31 (4), October 2024
Pages: 98–107
www.Ejimmunology.org
https://doi.org/10.55133/eji.310410
Sylvia T. Kamal, Mohamed A. Elshayeb, Menna Allah Z. Abou Elwafa, Radwa H. A. ElAdawy, Mariam A. Mohamed, and Osama M. Abdel Latif
Department of Internal Medicine, Allergy & Clinical Immunology, Faculty of Medicine, Ain Shams University, Cairo, Egypt. Corresponding author:
Mariam A. Mohamed, Department of of Internal Medicine, Allergy & Clinical Immunology, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
Email: : mariammamadouh@med.asu.edu.eg

 

Abstract

Chronic spontaneous urticaria (CSU) is a widespread disease with a complicated heterogenous pathophysiology. Increased intestinal permeability i.e., leaky gut has been linked to the pathology of many diseases. Zonulin was recently used as a marker for leaky guts. This study aimed to assess the relation between serum zonulin level and CSU and its possible relationship with disease activity. This was a comparative cross-sectional study, which included 97 CSU adult patients and 87 apparently healthy controls. CSU patients had significant lower zonulin level than controls (p<0.001). The median of serum zonulin level was equal to 2.93 ng/ml with interquartile range (IQR) (1.40-4.19) in the CSU group and of 3.92 ng/ml with IQR (2.97-4.69) in the control group. We found a positive correlation between serum zonulin and C-reactive protein with Pearson correlation coefficient of 0.2, (p=0.04). No significant correlation was found between serum zonulin level and urticaria activity score 7 or total immunoglobulin E level. In conclusion, this study found that serum zonulin level is lower in CSU patients than in controls which could be attributed to food restriction, severity of the CSU disease and/or drug intake in the CSU cases.

Keywords:

Chronic spontaneous urticaria, Zonulin, urticaria activity score 7, Intestinal barrier, leaky gut, C reactive protein

Date received: 16 February 2024; accepted: 22 September 2024

PMID:
39425648

 

Full Text